InvestSMART

Kazia Therapeutics Limited (ASX: KZA) - Announcements

DELISTED - Current share price for KZA : $0.080

ASX company news and announcements for Kazia Therapeutics Limited (KZA) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Kazia Therapeutics Limited (KZA) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Kazia Therapeutics Limited (KZA), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Kazia Therapeutics Limited (KZA)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Kazia Shareholder Presentation 16 Jul 2018 9:48AM $0.490 $0.080 fallen by 83.67%
- Kazia divests ATM program 13 Jul 2018 9:19AM $0.490 $0.080 fallen by 83.67%
- Kazia shareholder information sessions UPDATE 10 Jul 2018 9:24AM $0.470 $0.080 fallen by 82.98%
- Kazia change in interests of substantial shareholder 3 Jul 2018 1:51PM $0.450 $0.080 fallen by 82.22%
- Kazia Shareholder Information Sessions 25 Jun 2018 4:49PM $0.440 $0.080 fallen by 81.82%
- Kazia presents at Gold Coast Investment Showcase 21 Jun 2018 10:07AM $0.500 $0.080 fallen by 84%
- Kazia releases preliminary Cantrixil Phase I data 19 Jun 2018 8:34AM $0.615 $0.080 fallen by 86.99%
- Progress Report 21 May 2018 12:17PM $0.710 $0.080 fallen by 88.73%
- Kazia Shareholder Newsletter 11 May 2018 12:21PM $0.715 $0.080 fallen by 88.81%
- Kazia commences Phase II clinical study of GDC-0084 29 Mar 2018 7:51AM $0.735 $0.080 fallen by 89.12%
- Kazia presentation to Proactive Investors CEO series 19 Mar 2018 10:33AM $0.795 $0.080 fallen by 89.94%
- Notice of change in interests of substantial holder 7 Mar 2018 10:40AM $0.710 $0.080 fallen by 88.73%
- Kazia responds to share trading on ASX and Nasdaq 6 Mar 2018 11:21AM $0.750 $0.080 fallen by 89.33%
- Kazia receives FDA orphan drug designation for GDC 0084 23 Feb 2018 3:24PM $0.680 $0.080 fallen by 88.24%
- Kazia Appendix 4D, Half yearly accounts and Chairmans letter 21 Feb 2018 4:57PM $0.630 $0.080 fallen by 87.30%
- Kazia change of address 19 Feb 2018 5:25PM $0.575 $0.080 fallen by 86.09%
- Kazia receives $4m R&D tax rebate 19 Feb 2018 9:54AM $0.570 $0.080 fallen by 85.96%
- Kazia Appendix 3B 5 Feb 2018 4:26PM $0.550 $0.080 fallen by 85.45%
- Notice of change of interests of substantial holder 30 Jan 2018 11:19AM $0.620 $0.080 fallen by 87.10%
- Receipt of securities in Noxopharm Limited (NOX) 22 Jan 2018 10:04AM $0.430 $0.080 fallen by 81.40%
- Kazia change of interests of substantial shareholder 15 Jan 2018 4:14PM $0.400 $0.080 fallen by 80%
- Kazia presentation to Biotech Showcase 10 Jan 2018 10:09AM $0.390 $0.080 fallen by 79.49%
- NOX: Kazia Therapeutics Ltd and Noxopharm Ltd 27 Dec 2017 8:24AM $0.420 $0.080 fallen by 80.95%
- Kazia Therapeutics and Noxopharm 27 Dec 2017 8:24AM $0.420 $0.080 fallen by 80.95%
- GDC 0084 study update 21 Dec 2017 10:36AM $0.340 $0.080 fallen by 76.47%

451 - 475 of 476 results

Page 19 of 20

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.